CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
We have now added a new section called the "Assay History List" to the "At A Gla...